Compare Stocks: CLRB, ATHE, ELOX, and TLPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.37 +4.7%	$4.25	$2.66 ▼ $5.89	$61.09M	0.27	26,121 shs	21,265 shs
CLRB Cellectar Biosciences	$1.53 -8.6%	$2.37	$1.46 ▼ $5.59	$14.43M	0.58	384,858 shs	192,536 shs
ELOX Eloxx Pharmaceuticals	$14.84 -3.7%	$16.74	$8.20 ▼ $23.40	$59.95M	-1960.42	47,282 shs	45,689 shs
TLPH Talphera	$1.11 -4.3%	$1.23	$0.69 ▼ $1.57	$57.62M	0.67	239,555 shs	107,624 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	-6.67%	-8.00%	-29.07%	-41.35%	-24.24%
CLRB Cellectar Biosciences	-6.18%	-8.74%	-29.54%	-38.15%	-71.11%
ELOX Eloxx Pharmaceuticals	-0.64%	+2.73%	+2.73%	+40.73%	+1,400,809.09%
TLPH Talphera	+2.65%	-2.52%	-3.33%	-2.52%	+22.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.37 +4.7%	$4.25	$2.66 ▼ $5.89	$61.09M	0.27	26,121 shs	21,265 shs
CLRB Cellectar Biosciences	$1.53 -8.6%	$2.37	$1.46 ▼ $5.59	$14.43M	0.58	384,858 shs	192,536 shs
ELOX Eloxx Pharmaceuticals	$14.84 -3.7%	$16.74	$8.20 ▼ $23.40	$59.95M	-1960.42	47,282 shs	45,689 shs
TLPH Talphera	$1.11 -4.3%	$1.23	$0.69 ▼ $1.57	$57.62M	0.67	239,555 shs	107,624 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	-6.67%	-8.00%	-29.07%	-41.35%	-24.24%
CLRB Cellectar Biosciences	-6.18%	-8.74%	-29.54%	-38.15%	-71.11%
ELOX Eloxx Pharmaceuticals	-0.64%	+2.73%	+2.73%	+40.73%	+1,400,809.09%
TLPH Talphera	+2.65%	-2.52%	-3.33%	-2.52%	+22.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.57	Moderate Buy	$10.00	192.74% Upside
CLRB Cellectar Biosciences	2.80	Moderate Buy	$11.00	574.43% Upside
ELOX Eloxx Pharmaceuticals	3.00	Buy	$38.33	157.62% Upside
TLPH Talphera	2.25	Hold	$3.00	171.49% Upside

Current Analyst Ratings Breakdown

Latest CLRB, ATHE, ELOX, and TLPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$32.00
9/18/2026	ELOX Eloxx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy	$32.00
9/15/2026	ATHE Alterity Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
9/15/2026	ATHE Alterity Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
8/24/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/20/2026	ELOX Eloxx Pharmaceuticals	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	ELOX Eloxx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/13/2026	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
8/11/2026	ATHE Alterity Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$12.00
8/11/2026	ATHE Alterity Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$2.00
8/11/2026	ATHE Alterity Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.60 per share	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$1.89 per share	N/A
ELOX Eloxx Pharmaceuticals	$6.36M	9.45	N/A	N/A	($85.17) per share	-0.17
TLPH Talphera	$30K	1,912.02	N/A	N/A	$0.37 per share	2.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$15.88M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	-$21.79M	-$3.84	N/A	N/A	N/A	N/A	-185.35%	-115.42%	10/29/2026 (Estimated)
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	-$14.29M	-$0.27	N/A	N/A	N/A	N/A	-87.28%	-51.36%	11/11/2026 (Estimated)

Latest CLRB, ATHE, ELOX, and TLPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CLRB Cellectar Biosciences	-$0.52	-$0.57	-$0.05	-$0.57	$12.00 million	N/A
8/13/2026	Q2 2026	TLPH Talphera	-$0.0625	-$0.06	+$0.0025	-$0.06	N/A	N/A
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
7/30/2026	Q4 2026 TU	ATHE Alterity Therapeutics	N/A	-$0.28	N/A	-$0.28	N/A	$0.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	14.52	14.52
CLRB Cellectar Biosciences	N/A	6.66	6.66
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
TLPH Talphera	N/A	4.29	4.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
CLRB Cellectar Biosciences	16.41%
ELOX Eloxx Pharmaceuticals	2.90%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
CLRB Cellectar Biosciences	2.58%
ELOX Eloxx Pharmaceuticals	25.90%
TLPH Talphera	3.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	11	18.13 million	11.09 million	Not Optionable
CLRB Cellectar Biosciences	11	9.45 million	9.21 million	No Data
ELOX Eloxx Pharmaceuticals	7	4.04 million	2.99 million	N/A
TLPH Talphera	12	51.91 million	50.09 million	Optionable

CLRB, ATHE, ELOX, and TLPH Headlines

Recent News About These Companies

Talphera (TLPH) Stock Forecast & Price Target

September 30, 2026 | investing.com

Talphera (TLPH) upgraded to buy: Here's what you should know

September 21, 2026 | msn.com

Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 3, 2026 | prnewswire.com

Talphera Earnings Call Highlights Nafamostat Momentum

August 23, 2026 | tipranks.com

Talphera (TLPH) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Talphera, Inc. (TLPH) Q2 FY2026 earnings call transcript

August 14, 2026 | finance.yahoo.com

Talphera, Inc. (TLPH) Stock Major Holders - Yahoo Finance

August 13, 2026 | finance.yahoo.com

Talphera Inc (TLPH) (Q2 2026) Earnings Call Highlights: NEPHRO Study Enrollment Hits 75% as ...

August 13, 2026 | uk.finance.yahoo.com

Talphera signals ~$200,000 annual U.S. CRRT procedures in 2027 market sizing as NEPHRO CRRT reaches 75% enrollment

August 13, 2026 | seekingalpha.com

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

August 13, 2026 | seekingalpha.com

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | aol.comA

Talphera Q2 2026 earnings preview

August 11, 2026 | msn.com

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

August 5, 2026 | prnewswire.com

Talphera, Inc. Common Stock

July 15, 2026 | fxempire.comF

Talphera (TLPH) CEO Angotti buys $85k in shares

May 21, 2026 | investing.com

Talphera Earnings Call Highlights NEPHRO Trial Momentum

May 19, 2026 | tipranks.com

Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...

May 15, 2026 | finance.yahoo.com

Talphera Earnings Call Highlights Trial Momentum, Risks

May 14, 2026 | tipranks.com

Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026 | finanznachrichten.de

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

May 13, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLRB, ATHE, ELOX, and TLPH Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$3.37 +0.15 (+4.66%)

As of 04:00 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Cellectar Biosciences NASDAQ:CLRB

$1.52 -0.15 (-8.92%)

As of 04:00 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Eloxx Pharmaceuticals NASDAQ:ELOX

$14.84 -0.57 (-3.70%)

As of 02:58 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Talphera NASDAQ:TLPH

$1.11 -0.05 (-4.31%)

As of 04:00 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLRB, ATHE, ELOX, and TLPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLRB, ATHE, ELOX, and TLPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLRB, ATHE, ELOX, and TLPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLRB, ATHE, ELOX, and TLPH Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

Cellectar Biosciences NASDAQ:CLRB

Eloxx Pharmaceuticals NASDAQ:ELOX

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLRB, ATHE, ELOX, and TLPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLRB, ATHE, ELOX, and TLPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLRB, ATHE, ELOX, and TLPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLRB, ATHE, ELOX, and TLPH Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

Cellectar Biosciences NASDAQ:CLRB

Eloxx Pharmaceuticals NASDAQ:ELOX

Talphera NASDAQ:TLPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools